Latest research on Eprex

Human erythropoietin (recombinant), produced by CHO cells.

Eprex indications

Finally, the first synthetic EPO (Epogen) was approved by the FDA in 1989 and within a few years it was clear that EPO can have profound effects on maximal oxygen transport (VO2 max) [18] in humans and was being used to enhance athletic performance by the early 1990s. [source, 2014]
Using Epogen can lead to death or other serious side effects’ [14]. [source, 2013]
The possible adverse effects of erythropoiesis stimulators such as Procrit are well known to induce thromboembolism if not closely monitored. [source, 2013]
In conclusion, Procrit and other erythropoiesis stimulating drugs, while intended for the treatment of anemia due to the effect of concomitantly administered chemotherapy, can cause significant morbidity and mortality with an increased risk of cardiovascular events, gastrointestinal bleeding, thromboembolism and stroke. [source, 2013]
As before with Neupogen, combining A(1-7) with Epogen has hematological effects outside of the erythroid lineage in that the concentration of circulating neutrophils was increased with this combination. [source, 2013]
However, in studies in rats these prohypertensive effects of Epogen were offset by increased NO generation in the endothelial cells of the kidney [33]. [source, 2011]
Since CKD impairs NO generation, this offsetting effect may be diminished and this may explain why the hypertensive effects of Epogen are more pronounced in patients with CKD and hypertension [34]. [source, 2011]
No such effect was observed in patients taking Epogen. [source, 2011]